Anti-fibrotic peptide shows early promise against interstitial lung disease

The M10 peptide reduces collagen production and reverses fibrotic damage due to systemic sclerosis (SSc)-related interstitial lung disease (ILD), preclinical findings suggests. ILD is one of the deadliest complications of SSc, a chronic autoimmune disease characterized by vasculopathy, autoimmunity, and excessive collagen production and deposition. Lung fibrosis carries a high risk of morbidity/mortality in SSc patients.